Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Recruiting2
Completed1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

completed125%
enrolling_by_invitation125%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
enrolling_by_invitation

Histiocytosis in Injecting Drug Users

NCT06573671
completednot_applicable

Analyzes of Nasal Tissue-resident Memory Immune Cells and Peripheral Memory Cells Able to Migrate to Airway Tissues (MUCOVAC)

NCT06469359
recruiting

Immune Homeostasis in Sepsis and Septic Shock

NCT04448951
recruiting

Fatty Liver Disease in Nordic Countries

NCT04340817

Clinical Trials (4)

Showing 4 of 4 trials
NCT06573671

Histiocytosis in Injecting Drug Users

Enrolling By Invitation
NCT06469359Not Applicable

Analyzes of Nasal Tissue-resident Memory Immune Cells and Peripheral Memory Cells Able to Migrate to Airway Tissues (MUCOVAC)

Completed
NCT04448951

Immune Homeostasis in Sepsis and Septic Shock

Recruiting
NCT04340817

Fatty Liver Disease in Nordic Countries

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
4